EFPIA - NEWSLETTER

EFPIA Newsletter 01 July 2021

COVID-19 Vaccines: Meeting the world's need

The industry is on target to exceed 11 billion vaccine doses by the end of 2021. But rapid action is needed to tackle manufacturing bottlenecks. Watch the video here:

At present it can take between 90 to 120 days to manufacture a single batch of COVID-19 vaccine whether mRNA, viral vector or recombinant protein. Companies are working to reduce lead times as much as possible. Read more in this blog.

Catch up with EFPIA's recent events

Beating cancer: Looking ahead, learning from the past

COVID-19 has had an impact on every patient access milestone and will have a profound effect on patient outcomes if no action is taken to make up lost ground in screening, treatment and surgery.

How can COVID-19 treatments help us on the road to recovery?

While vaccination programmes continue to scale up around the world, therapeutics play a key role in saving lives, freeing up capacity in intensive care units and treating patients living with long-COVID.

Together, we can be #StrongerThanEver in the fight against cancer

When COVID hit, it felt like the whole world stopped. But cancer didn’t stop, so neither did we. Looking at what we have learnt, by continuing to work together, we can be #StrongerThanEver in the fight against cancer. Watch our video here:

The COVID-19 pandemic has hit every aspect of cancer care, putting patients at higher risk of poor outcomes. Despite the challenges, there have been some positive features of Europe’s response to the pandemic, including the adoption of digital health and greater agility in the development and approval of innovative solutions.

Stakeholders have identified six recommendations which can make cancer care delivery more resilient to disruptions and more sustainable in the post-pandemic world. Read them here.

What we are reading

MEP: Public-private partnerships needed to face silent threat of AMR 01 July 2021 (Euractiv)

Incentives alone are not enough to cope with rare disease, report says 01 July 2021 (Euractiv)

Nitrosamine Impurities – Understanding Risks, Overcoming Challenges 30 June 2021 (Technology Networks)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶